Skip to main content

Table 2 Use of biologic agents after withdrawal of infliximab therapy

From: Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

New biologic therapy Reason for withdrawal Total
  Lack of efficacy Patient request Safety issues  
None 24 3 44 71
Adalinumab 10 23 3 36
Etanercept 6 4 8 18
Rituximab 8 0 1 9
Abatacept 4 0 4 8
Total 52 30 60 142